GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Days Payable

Kymera Therapeutics (Kymera Therapeutics) Days Payable : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Days Payable?

Kymera Therapeutics's average Accounts Payable for the three months ended in Mar. 2024 was $6.94 Mil. Kymera Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Kymera Therapeutics's Days Payable or its related term are showing as below:

KYMR's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 148.12
* Ranked among companies with meaningful Days Payable only.

Kymera Therapeutics's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same


Kymera Therapeutics Days Payable Historical Data

The historical data trend for Kymera Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Days Payable Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial - - - - -

Kymera Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kymera Therapeutics's Days Payable

For the Biotechnology subindustry, Kymera Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kymera Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Kymera Therapeutics's Days Payable falls into.



Kymera Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Kymera Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (4.335 + 7.075) / 2 ) / 0*365
=5.705 / 0*365
=N/A

Kymera Therapeutics's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

Days Payable (Q: Mar. 2024 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2023 ) + Accounts Payable (Q: Mar. 2024 )) / count ) / Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=( (7.075 + 6.812) / 2 ) / 0*365 / 4
=6.9435 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kymera Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Kymera Therapeutics (Kymera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 230, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Executives
Jeffrey W. Albers director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Ellen Chiniara officer: Chief Legal Officer 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jeremy G Chadwick officer: Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs officer: Chief Financial Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan director KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi director, officer: President and CEO C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Jared Gollob officer: Chief Medical Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth officer: Chief Scientific Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Elaine Caughey officer: Chief Business Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Kymera Therapeutics (Kymera Therapeutics) Headlines

From GuruFocus